Neurodegeneration is a hallmark sign of Alzheimer’s, epilepsy, multiple sclerosis, traumatic brain injury and a host of other serious brain illnesses. Until now, brain MRI has been limited in its assessment of neurodegeneration, often reading a brain as normal even when signs of disease are present.
NeuroQuant® is the first FDA-cleared and CE-marked solution to quantify the volume of certain brain structures, comparing them to corresponding normal values of patients the same age, gender and cranial volume.
WHAT ARE THE MAIN BENEFITS?
NeuroQuant® can help physicians evaluate if there is volume change of certain brain structures. Volume loss or atrophy of the hippocampi can be seen in traumatic brain injury, seizure/epilepsy, or neurodegenerative diseases such as Alzheimer's disease.
NeuroQuant® is useful for tracking volume changes in white matter and brain cortical structures over months to years. This is useful for providers to track effects of therapy or intervention as well as progression of neurodegenerative diseases such as Alzheimer's disease.
WHAT DOES NEUROQUANT® REPORT?
The five volumetric reports provide objective data so physicians can detect and measure changes in brain anatomy - the key step in evaluating whether a patient is aging normally or experiencing the early stages of disease.
The volumetric reports include quantitative data on: 1) age-related atrophy, 2) hippocampal volume asymmetry, 3) multi-structure atrophy, 4) triage brain atrophy, 5) brain development, 6) general morphometry, and 7) longitudinal studies.
All reports are interpreted by a board-certified neuroradiologist with 15 years experience.